Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 22,634,728
  • Shares Outstanding, K 535,100
  • Annual Sales, $ 9,429 M
  • Annual Income, $ 848 M
  • 36-Month Beta 1.14
  • Price/Sales 2.20
  • Price/Cash Flow N/A
  • Price/Book 1.90

Price Performance

See More
Period Period Low Period High Performance
1-Month
35.16 +19.45%
on 01/24/17
42.70 -1.64%
on 02/21/17
+4.93 (+13.30%)
since 01/20/17
3-Month
33.79 +24.30%
on 12/07/16
42.70 -1.64%
on 02/21/17
+5.68 (+15.64%)
since 11/22/16
52-Week
33.60 +25.00%
on 11/03/16
50.40 -16.67%
on 08/09/16
-4.81 (-10.28%)
since 02/22/16

Most Recent Stories

More News
Where Are the Best Buying Opportunities in Stocks Right Now?

With stocks hitting new record highs, you might think there???s nothing left to buy. But some of the biggest money managers beg to differ.

MYL : 42.00 (-0.71%)
AGN : 246.32 (-0.34%)
KEG : 33.35 (-0.92%)
CMG : 427.61 (-1.10%)
M : 32.36 (+0.22%)
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.

Mylan N.V. (MYL) and Biocon Ltd. announced that the FDA has accepted their biologics license application for a biosimilar version of Amgen's (AMGN) Neulasta (pegfilgrastim) - MYL-1401H.

MYL : 42.00 (-0.71%)
RHHBY : 30.6100 (-0.21%)
AMGN : 172.61 (-0.31%)
SNSS : 4.25 (unch)
Blog Coverage The Biologics License Application for Mylan-Biocon's Proposed Biosimilar - Pegfilgrastim, Gets Accepted by US FDA for Review

Upcoming AWS Coverage on Mallinckrodt Post-Earnings Results

MYL : 42.00 (-0.71%)
MNK : 54.21 (+0.18%)
AMGN : 172.61 (-0.31%)
Covered Call Reports for Coty Inc., Fiat Chrysler Auto, Lowes, Mylan and PepsiCo include trade ideas from InvestorsObserver.

InvestorsObserver issues critical PriceWatch Alerts for COTY, FCAU, LOW, MYL, and PEP.

FCAU : 11.38 (-0.44%)
MYL : 42.00 (-0.71%)
LOW : 76.80 (-0.58%)
PEP : 109.41 (+0.05%)
COTY : 18.84 (-1.67%)
U.S. FDA Accepts Biologics License Application (BLA) for Mylan and Biocon's Proposed Biosimilar Pegfilgrastim for Review

Mylan N.V. (NASDAQ, TASE: MYL) and Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced that the U.S. Food and Drug Administration (FDA) has accepted Mylan's Biologics License Application (BLA)...

MYL : 42.00 (-0.71%)
Mylan Applauds the Generic Pharmaceutical Association's Rebrand to the Association for Accessible Medicines

Mylan N.V. (NASDAQ, TASE: MYL) today applauds the rebranding of the Generic Pharmaceutical Association (GPhA) to the Association for Accessible Medicines (AAM).

MYL : 42.00 (-0.71%)
Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance

Teva Pharmaceutical Industries Ltd. (TEVA) reported fourth-quarter 2016 earnings of $1.34 per share (including equity compensation expenses), which beat the Zacks Consensus Estimate of $1.28.

MYL : 42.00 (-0.71%)
AGN : 246.32 (-0.34%)
NVS : 76.85 (-0.25%)
TEVA : 35.97 (-1.86%)
Company announces pause for drug after price criticism

WASHINGTON (AP) — Marathon Pharmaceuticals announced Monday that it will temporarily halt the rollout of a drug to treat genetic muscle deterioration just hours after two members of Congress expressed...

MYL : 42.00 (-0.71%)
Mylan to Host Investor Day on March 1, 2017 in New York City

Mylan N.V. (NASDAQ, TASE: MYL) today announced that it will host an Investor Day on March 1, 2017 in New York City. Mylan CEO Heather Bresch and the company's senior leadership team will present the company's...

MYL : 42.00 (-0.71%)
Momenta Says District of Delaware Invalidates Teva's MS Drug

Shares of Momenta Pharmaceuticals, Inc. (MNTA) shot up 25.2% after Mylan N.V. (MYL) announced that the United States District Court for the District of Delaware has issued a decision in favor of the latter...

MYL : 42.00 (-0.71%)
NVS : 76.85 (-0.25%)
MNTA : 15.10 (-5.92%)
TEVA : 35.97 (-1.86%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Support & Resistance

2nd Resistance Point 42.49
1st Resistance Point 42.25
Last Price 42.00
1st Support Level 41.81
2nd Support Level 41.61

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.